Menz G, Dolecek C, Schönheit-Kenn U, Ferreira F, Moser M, Schneider T, Suter M, Boltz-Nitulescu G, Ebner C, Kraft D, Valenta R
Institut für Allgemeine und Experimentelle Pathologie, AKH, Universität Wien, Osterreich.
Pneumologie. 1996 Sep;50(9):632-40.
Type I allergy represents a severe health problem in industrialized countries where up to 20% of the population suffers from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death.
The aim of this study was to evaluate recombinant Bet v 1, the major birch pollen allergen for in vivo and in vitro diagnosis of birch pollen allergy.
A group of 51 birch pollen allergic patients and eight non-allergic control individuals were tested for birch pollen allergy by skin-prick and intradermal testing, comparing commercial birch pollen extracts with recombinant Bet v 1. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting.
Recombinant Bet v 1 allowed accurate in vivo and in vitro diagnosis of tree pollen allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA, Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v 1.
Our results document that recombinant Bet v 1 produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch pollen allergy in > 95% of birch pollen allergic patients.
在工业化国家，I型过敏是一个严重的健康问题，高达20%的人口患有过敏性鼻炎、结膜炎和过敏性支气管哮喘，严重时会发生过敏反应，导致死亡。
本研究旨在评估重组Bet v 1，这是桦树花粉过敏体内和体外诊断的主要桦树花粉过敏原。
通过皮肤点刺试验和皮内试验，对51名桦树花粉过敏患者和8名非过敏对照个体进行桦树花粉过敏检测，将市售桦树花粉提取物与重组Bet v 1进行比较。通过放射变应原吸附试验（RAST）、酶联免疫吸附测定（ELISA）和免疫印迹法，用天然和重组过敏原进行定量和定性血清学检测。
重组Bet v 1对49/51名受试患者的树花粉过敏进行了准确的体内和体外诊断。在任何体外检测系统（ELISA、Westernblot）或使用重组Bet v 1进行皮肤检测（皮肤点刺、皮内试验）时均未获得假阳性结果。
我们的结果表明，在细菌表达系统中产生的重组Bet v 1能够对超过95%的桦树花粉过敏患者进行准确的体外和体内桦树花粉过敏诊断。
